Podcasts about atai life sciences

In this CME podcast, Dr. Andrew Cutler and Dr. Roger McIntyre discuss the use of potentially unsafe drug combinations in patients with treatment-resistant psychiatric conditions. They review situations where complex medication regimens may be necessary and how clinicians may proceed in these instances. By addressing these topics, the podcast offers guidance on balancing the potential benefits of combination therapies with the risks associated with polypharmacy in psychiatric care.  Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Identify common potentially unsafe drug combinations that may be considered in treatment-resistant cases Evaluate the risks and benefits of prescribing potentially unsafe drug combinations for treatment-resistant patients, considering factors such as efficacy, adverse effects, and patient-specific characteristics Develop strategies to monitor and manage patients prescribed potentially unsafe drug combinations Accreditation: In support of improving patient care, this activity has been planned and implemented by HMP Education and Neuroscience Education Institute (NEI). HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with synchronized audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 1 hour. Released: March 26, 2025*   Expiration: March 25, 2028 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD25-01 Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ HMP Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurse: ANCC contact hours This continuing nursing education activity awards 1.00 contact hour. Provider approved by the California Board of Registered Nursing, Provider #18006 for 1.00 contact hour. Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.00 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.00 contact hour (.10 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI and HMP Education must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and are unable to report your claimed credit after this 60-day period. Ensure your profile includes your DOB and NABP ID. Physician Associate/Assistant: AAPA Category 1 CME credits HMP Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credits for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.00 AAPA Category 1 credit. Approval is valid until March 25, 2028. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. This activity awards 1.00 CE Credit. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, HMP Education is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1.00 general continuing education credit. Non-Physician Member of the Healthcare Team: Certificate of Participation HMP Education awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, and cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI and HMP Education take responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any relevant financial relationships were mitigated prior to the activity being planned, developed, or presented. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, New York Chief Medical Officer, Neuroscience Education Institute, Malvern, Pennsylvania Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Roger S. McIntyre, MD, FRCPC Professor, Departments of Psychiatry and of Pharmacology, University of Toronto, Toronto, Ontario, Canada CEO, Braxia Scientific Corp, Toronto, ON, Canada Grant/Research: Canadian Institutes of Health Research, China National Natural Research Foundation, Global Alliance for Chronic Diseases, Milken Institute Consultant/Advisor: Alkermes, Atai Life Sciences, Axsome, Bausch Health, Biogen, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Mitsubishi Tanabe, Neumora Therapeutics, Neurocrine, NewBridge Pharmaceuticals, Novo Nordisk, Otsuka, Pfizer, Purdue, Sage, Sanofi, Sunovion, Takeda, Viatris The remaining Planning Committee members, Content Editors, Peer Reviewer, NEI and HMP planners/staff have no financial relationships to disclose. NEI and HMP Education planners and staff include Gabriela Alarcón, PhD, Ali Holladay, Andrea Zimmerman, EdD, CHCP, Brielle Calleo, and Steven S. Simring, MD, MPH. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported solely by the provider, NEI.

Pursuing social anxiety disorder with MDMA. Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds (1:30). Standing on the shoulders of Johnson & Johnson's Spravato (4:00). Upcoming milestones and clinical trials (13:15). Psychedelic industry sentiment; RFK Jr influence (30:40).Show Notes:Psychedelic Stocks: Focus On Their CashDeep Dive: Atai Life SciencesFDA's MDMA Decision A Setback, But Long-Term Outlook For Psychedelic Stocks UnchangedRead our episode transcriptsFor full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO and co-founder Dr Srinivas Rao talked with Proactive's Stephen Gunnion about the promising results in strategic investee Beckley Psytech's Phase 2a study of BPL-003 for alcohol use disorder. Rao highlighted the significant unmet need in treating alcohol use disorder (AUD), which affects approximately 400 million people globally and contributes to 3 million deaths per year. The Phase 2a trial, though small with 12 participants, yielded promising results. Patients received a single dose of BPL-003 alongside cognitive behavioral therapy, leading to a 50% abstinence rate over three months. Additionally, heavy drinking days were reduced from 56% to 13%, while abstinent days increased from 33% to 81%. Looking ahead, atai Life Sciences is anticipating data from a larger Phase 2b study. Rao explained that BPL-003, a 5-MeO-DMT benzoate nasal spray, is being evaluated for its potential to provide long-lasting therapeutic effects with a single administration. This approach contrasts with existing treatments like Esketamine, which require frequent dosing. Rao emphasized that shorter-duration psychedelic treatments could ease the burden on patients and healthcare providers. By reducing the need for frequent visits, these therapies could make mental health treatment more accessible and scalable. To stay updated on atai Life Sciences' research, subscribe to Proactive's YouTube channel, like this video, and enable notifications for future updates. #ataiLifeSciences #PsychedelicTherapy #MentalHealth #AlcoholUseDisorder #BPL003 #DepressionTreatment #PharmaceuticalResearch #MedicalBreakthrough #InvestorNews #Biotech

In this episode, Dr. Alexandria Wise celebrates 15 years of innovation at CNS Summit 2024 by sitting down with Kevin Craig, Senior Vice President of Clinical Development at atai Life Sciences. Recorded from the floor of the conference, Kevin shares his journey from research and medicine to leading drug development in mental health, with a focus on the company's pioneering work in psychedelics.This episode delves into the complexities of drug development in the psychedelic space, the importance of global accessibility, and the profound impact of patient involvement in clinical trial design. Kevin also shares his perspective on the future of the life sciences industry, emphasizing the role of big data, biomarkers, and efficient trial models in advancing mental health care.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

In this CME episode, Drs. Andrew Cutler and Roger McIntyre discuss the challenges and importance of diagnosing bipolar disorder as early as possible in the course of the illness. They also review strategies to achieve a correct diagnosis to provide the most efficacious and tolerable treatments available for bipolar disorder. Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Employ effective screening tools and assessment strategies to enhance diagnostic accuracy and achieve early diagnosis of bipolar disorder Develop patient-centered treatment plans that incorporate current evidence and individual patient factors Utilize shared decision-making approaches to optimize treatment outcomes for patients with bipolar disorder Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 1 hour Released: November 01, 2024*   Expiration: October 31, 2027 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-BD Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 1.0 ANCC contact hour Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.0 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.0 contact hour (.10 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.0 AAPA Category 1 credit. Approval is valid until OCtober 31, 2027. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1 general continuing education credits. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, New York Chief Medical Officer, Neuroscience Education Institute, Malvern, Pennsylvania Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Roger S. McIntyre, MD, FRCPC Professor, Departments of Psychiatry and of Pharmacology, University of Toronto, Toronto, Ontario, Canada CEO, Braxia Scientific Corp, Toronto, Ontario, Canada Grant/Research: Canadian Institutes of Health Research, China National Natural Research Foundation, Global Alliance for Chronic Diseases, Milken Institute Consultant/Advisor: Alkermes, Atai Life Sciences, Axsome, Bausch Health, Biogen, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Mitsubishi Tanabe, Neumora Therapeutics, Neurocrine, NewBridge Pharmaceuticals, Novo Nordisk, Otsuka, Pfizer, Purdue, Sage, Sanofi, Sunovion, Takeda, Viatris The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O'Brien, Gabriela Alarcón, PhD, Andrea Zimmerman, EdD, CHCP, and Brielle Calleo. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported by an unrestricted educational grant from Alkermes, Inc.

ATAI Life Sciences & Compass Pathways Co-Founder Christian Angermayer joins the show to talk about the roadblocks to getting psychedelics legal in the US and the best way to effectively treat mental health with them. Christian has been making waves recently after appearing on Joe Rogan, and has the backing of Peter Thiel. We've been talking alot about the potential of psychedelics in the past year, and after the FDA's recent disappointing decision... Christian tells us why it may not be all bad news. Sam handles the interview with Christian and then Derek hops in with Sam to talk about their interest in this investment. The views and opinions expressed by Christian Angermayer in this episode are his own and do not necessarily represent those of atai Life Sciences. Discussed:  Dr. Nutt's "Drug Harm" Chart ATAI Investor Relations Compass Pathways Investor Relations Christian Angermayer's Substack ILAB 294: Matthew "Whiz" Buckley on Flying in Top Gun, Trading Options & Taking Psychedelics Where we are: Johnny FD – Kyiv, Ukraine / IG @johnnyfdj Sam Marks - Bangkok, Thailand / IG @sammarks12 Derek – Los Angeles, USA / IG @DerekRadio Sponsor: ShopifyShopify helps you sell EVERYWHERE. From their all-in-one ecommerce platform, to their in-person POS system–wherever and whatever you're selling, Shopify's got you covered. Sign up for a $1 per month trial period now at Shopify.com/ilab ILAB PatreonJoin the Invest Like a Boss Patreon now and get tons of bonus content, including additional episodes, full quarterly updates including account screenshots and more for as low as $5/month at Patreon.com/InvestLikeaBoss Time Stamp: 00:21 - Sam/Derek Intro 06:09 - Interview with Christian Begins 32:00 - Why FDA Approval is Taking So Long 57:07 - The State of Psychedelic Stocks 01:08:13 - Sam/Derek Outro - Would They Invest If you enjoyed this episode, do us a favor and share it! If you haven't already, please take a minute to leave us a 5-star review on Apple Podcasts and Spotify. Copyright 2024. All rights reserved. Read our disclaimer here.

atai Life Sciences co-founder and co-CEO Dr Srinivas Rao takes Proactive's Stephen Gunnion through the positive results from the Phase 1b trial for VLS-01, emphasizing its excellent tolerability and potential as a best-in-class treatment option. The trial revealed that the formulation exceeded expectations, particularly in terms of pharmacokinetics, with results comparable to intravenous administration. VLS-01 is being developed for treatment-resistant depression, a condition that impacts the lives of an estimated 100 million people globally. Srinivas emphasizes the potential of VLS-01 as a best-in-class treatment option, with excellent tolerability, patient-friendly administration and a short 2-hour in-clinic treatment time. The trial revealed that the formulation exceeded expectations, particularly in terms of pharmacokinetics, with results comparable to intravenous administration. Rao noted that the next steps include advancing the 120mg dose into a robust Phase 2 trial for treatment-resistant depression, with results expected by the end of next year. He also addressed recent FDA decisions regarding MDMA and how atai's approach in trial design avoids similar pitfalls. Beyond VLS-01, Rao highlighted that the company is progressing its clinical development plans for EMP-01, which is oral R-MDMA, with a Phase 2 trial for social anxiety disorder set to initiate by the end of the year. Don't forget to like this video, subscribe to our channel, and turn on notifications to stay updated with our latest content. #AtaiLifeSciences #ClinicalTrials #VLS01 #MentalHealth #PharmaceuticalResearch #DepressionTreatment #Phase2Trial #FDA #Biotech #DrugDevelopment #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Atai Life Sciences co-founder and CEO Florian Brand discussed initial results from Beckley Psytech's phase 1 trial of its patent-protected psilocin ELE-101 in patients with major depressive disorder. Brand explained that ELE-101 is an intravenous (IV) formulation of psilocin, the active metabolite of psilocybin, developed for depression treatment. The IV formulation aims to reduce treatment duration to two hours, compared to the longer sessions required by traditional psilocybin and LSD treatments. Phase one trials in healthy participants showed that ELE-101 was well tolerated with no serious safety concerns and had a predictable pharmacokinetic profile, supporting dose selection for phase two trials. Brand highlighted the commencement of phase 2 trials with the first patient already dosed. This study involves 6 to 12 patients, with data expected in the second half of this year. atai Life Sciences is optimistic about the shorter treatment duration, potentially making it more convenient for patients and less burdensome for the healthcare system. Additionally, Brand mentioned their involvement with Compass Pathways, which is developing psilocybin therapy, and noted the importance of the two-hour treatment paradigm established by the intranasal esketamine spray, Spravato. This paradigm could be leveraged for their other compounds, such as BPL-003 and DMT, also being developed for depression treatment. #AtaiLifeSciences, #Elly101, #Psilocin, #Psilocybin, #DepressionTreatment, #IVFormulation, #Pharmacokinetics, #ClinicalTrials, #MentalHealth, #Psychedelics, #PhaseTwoTrials, #HealthcareInnovation, #CompassPathways, #Spravato, #Esketamine, #ShortDurationTherapy, #BPL003, #DMT, #Neuropsychiatry, #FlorianBrand #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

In this episode, hosts Katie Perry and Austin Hankwitz explore atai Life Sciences with Founder and Chairman Christian Angermayer, covering its mission and the rise of mental health issues. Together, they discuss the current state of psychedelic regulation, atai's drug development phases, how retail investors should approach Atai post-product launch, and the company's go-to-market strategy. $ATAI 00:00:00 START 00:01:20 What is atai Life Sciences? 00:08:55 The prevailing theory on the rapid rise of mental health issues 00:15:50 Regulatory bodies' openness to collaborating with atai 00:17:58 The current state of the regulation process for psychedelics 00:19:17 Phases of drug development and where atai currently is 00:24:00 How retail investors should be thinking about atai once the products go live 00:27:10 atai's go-to-market strategy 00:32:09 Current world leader who should have the psychedelic experience 00:35:28 What retail investors should be looking at in atai's earnings 00:40:13 Longevity and anti-aging effects of psychedelics After Earnings is brought to you by Stakeholder Labs and Morning Brew. For more go to https://www.afterearnings.com Follow Us X: https://twitter.com/AfterEarnings TikTok: https://www.tiktok.com/@AfterEarnings Instagram: https://www.instagram.com/afterearnings_/ Reach Out Email: afterearnings@morningbrew.com Learn more about your ad choices. Visit megaphone.fm/adchoices

atai Life Sciences co-founder and CEO Florian Brand takes Proactive's Stephen Gunnion through the significant advancements the company made in 2023 in developing innovative mental health therapies, particularly focusing on psychedelic-based treatments for depression. The company highlighted strategic investments and the progression of its programs, including BPL-003 R3 and ELE-101, both aimed at fitting within a two-hour in-clinic treatment window established by Spravato, an FDA-approved drug for depression. Atai's DMT program, BLS-01, also aimed at short-duration psychedelic therapies, was part of this focus. atai announced encouraging results from a Phase 2a trial of BPL-003 in treatment-resistant depression, showcasing rapid and durable antidepressant effects after a single dose. The company plans to advance this program through additional trials, including a Phase 2b study with results expected in the latter half of the year. Besides depression, atai is exploring treatments for opioid use disorder, with a pivot to an IV formulation of Ibogaine, aiming for improved safety and efficacy. For 2024, Atai anticipates significant milestones, including results from the KM-360 Phase 3 trial in Q4, marking an important development in psychedelic research. Additionally, a Phase 2b trial in cognitive impairment associated with schizophrenia is underway, testing a pro-cognitive neuromodulator, Olav-7, with results expected mid-next year. #AtaiLifeSciences, #MentalHealthInnovation, #PsychedelicTherapy, #DepressionTreatment, #TreatmentResistantDepression, #BPL-003, #DMTProgram, #IbogaineTreatment, #OpioidUseDisorder, #NeuropsychiatryResearch#ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

atai Life Sciences chief scientific officer Dr Srinivas Rao discusses the company's development candidate VLS-01, aimed at treating treatment-resistant depression, with Proactive's Stephen Gunnion. Rao explained that VLS-01 is a formulation of DMT, the active component in ayahuasca, known for its short-duration psychedelic effects. The innovation lies in its delivery method, an oral transmucosal film, resembling a Listerine strip, which dissolves inside the mouth over 20 minutes, providing a patient-friendly alternative to intravenous administration. Rao said this approach is designed to enhance the patient and healthcare provider experience, especially in settings not equipped for IV treatments. The ongoing Phase 1B trial seeks to confirm VLS-01's safety, tolerability, pharmacokinetics (PK), and pharmacodynamics, aiming for a psychoactive effect lasting 30-45 minutes with patients returning to baseline within two hours post-administration. Rao said this trial format follows the US treatment paradigm established by Spravato (esketamine) for depression. The trial will involve 16 healthy volunteers to assess the drug's impact, setting a baseline with intravenous DMT before testing up to three oral doses of VLSI-01. Initial results are expected in the second half of the year, with plans to proceed to Phase 2 trials involving patients with treatment-resistant depression to evaluate the compound's efficacy further. #AtaiLifeSciences #VLSI01 #TreatmentResistantDepression #DMT #PsychedelicMedicine #MentalHealth #Pharmaceuticals #ClinicalTrials #InnovativeTherapies #HealthcareInnovation #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

In der heutigen Folge von „Alles auf Aktien“ sprechen die Finanzjournalisten Daniel Eckert und Holger Zschäpitz über die Rückkehr von FOMO an der Wall Street, eine Hausse bei Biotech und den Bitcoin auf 2-Jahreshoch. Außerdem geht es um Qiagen, Volkswagen Vz., Boeing, Spirit AeroSystems, United Airlines, American Airlines, Airbus, Johnson & Johnson, Merck &. Co., Ambrx Biopharma, Harpoon Therapeutics, Atai Life Sciences, Bitcoin, Schweizerische Nationalbank, Nvidia, AMD, Marvell, Intel, Dell, HP, LG, Samsung Electronics, Mercedes Benz, Mobileye, Apple, Meta. Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hier findet ihr alle AAA-Bonus-Episoden bei WELT – dazu den AAA-Newsletter und noch weitere WELTplus-Inhalte: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Christian Angermayer ist Seriengründer und Investor aus Deutschland, der heute in London lebt. Mit seinem Family Office Apeiron Investment Group investiert er vornehmlich in Biotechunternehmen. Warum er überzeugt ist, dass die Lebenserwartung von Neugeborenen heute MEHRERE 100 Jahre beträgt, warum er die Zukunft in Psychodelischen Wirkstoffen sieht, seine Formel für Glück und wie er heute nochmal starten würde, verrät er uns im Interview.

Synopsis: We recorded this episode in December 2022 with Florian Brand and Srinivas Rao, the Co-Founders and CEO & CSO, respectively, of atai Life Sciences, a biopharmaceutical company that leverages a decentralized platform approach to incubate and accelerate the development of highly effective mental health treatments that address the unmet needs of patients, including psychedelics and digital therapeutics. Florian and Srinivas provide an overview of the neuropsychiatry landscape, the history of psychedelics within mental health, and the role COVID played in increasing mental health awareness. They also discuss the model at atai around drug development and how they approach tackling such a massive unmet need. Finally, Florian talks about how self-awareness can lead to healthier habits and decision-making, and the importance of investing in therapy. Biography: Florian Brand is the co-founder and Chief Executive Officer of atai Life Sciences. Prior to joining atai, Florian was starting and building user-centric technology companies as a serial entrepreneur. Florian suffered from anxiety in his youth and was able to achieve remission through a combination of psychotherapy and robust meditation practice. It was ultimately his experiences seeing his friends and loved ones failed by the mental healthcare system that inspired him to join the movement to transform the treatment landscape for patients who have been unable to find relief in currently available therapies. In 2022, Florian was recognized in Fortune's 40 Under 40 list spotlighting influential individuals shaping business and Business Insider's 30 Under 40 in Healthcare. Florian was also featured in Endpoint News' list of 20 Under 40 Innovators in Biotech in 2021. He is a proud member of the Founders Pledge, a global community of mission-aligned entrepreneurs dedicated to doing good. Srinivas Rao is the Chief Scientific Officer at atai Life Sciences. Dr. Rao has over 19 years of professional experience in the pharmaceutical and biotechnology industries. Prior to atai, Dr. Rao has held the titles of Chief Scientific, Medical, or Executive Officer at companies ranging from venture-backed startups to vertically-integrated, publicly-traded pharmaceutical companies. Dr. Rao completed an internship in Internal Medicine at Yale-New Haven Hospital. He received his Ph.D. in neurobiology from Yale Graduate School and his M.D. from Yale School of Medicine. He holds both a Bachelor of Science and Master of Science degree in Electrical Engineering from Yale College and Yale Graduate School, respectively.

Deborah Mash is neuroscientist, inventor and one of the world's foremost experts on the hallucinogenic drug ibogaine. She is the CEO and Founder of DemeRx Inc., a clinical stage drug development company advancing ibogaine and its active metabolite noribogaine for the treatment of opioid use disorder. DemeRx has partnered with ATAI Life Sciences -- a global biotech platform with a special focus on psychedelic medicine -- to develop ibogaine for those suffering from opioid use disorder. Building on the extensive human data available around ibogaine, DemeRx and ATAI will submit Clinical Trial Applications for a Phase II study in opioid-dependent patients to address the current opioid crisis in America. Deborah Mash is Professor of Neurology (Emeritus) and Molecular and Cellular Pharmacology at the University of Miami Miller School of Medicine. She has held uninterrupted NIH funding from the National Institute on Drug Abuse for over thirty years. She works with a team of scientists, clinicians and other researchers and entrepreneurs to bring discoveries to patients. Topics covered in this episode: Discoveries of the Brain Hallucinogenic Research Ibogaine Metabolites Withdrawls Pharmacology Rewiring the Brain Alkaloids in Plants Psychiatry & Psychedelics Referenced in the episode: The Lindsey Elmore Show Ep 202 | Drunk: Why We Drink and How It Civilized Us | Edward Slingerland To learn more about Deborah Mash and her work, head over to https://www.demerx.com/ __________________________________________________________ This is the perfect time to assess your current routines. What is serving you, what isn't, and is there anything that can help aid your health and wellness journey. This is where Sambucol comes in. They help support a healthy immune system so that you can keep moving, helping your daily dose of black elderberry to happen with ease. With a wide variety of products, Sambucol will pump up that immunity so that it can keep you moving. Listeners of Lindsey Elmore can get 15% off of $9.99 or more at www.SambucolUSA.com by using my promo code Lindsey15 at checkout! __________________________________________________________ Do you want to live a healthy lifestyle but you don't know where to find reliable health education, you don't have someone you can trust to lead you to which health and wellness options are out there. When you go to http://www.Wellnessmadesimple.us you can learn practical skills that you need to build a healthy lifestyle. You'll gain access to more than 85 videos, 11 hours of education and more education is always being added, and you'll join a community that has given more than 2400 positive reviews. All you have to do is get access, and right now we are offering half off of an annual subscription when you shop the code 2023Wellness and after that, watch the coursework, then implement daily changes positively transform your help you can feel better. Go to http://www.Wellnessmadesimple.us to get an annual subscription, and shop the code 2023Wellness for half off of your annual subscription. __________________________________________________________ __________________________________________________________ We hope you enjoyed this episode. Come check us out at www.lindseyelmore.com/podcast.

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Daniel Eckert und Holger Zschäpitz über einen Managementwechsel im Alibaba-Imperium, neue Alzheimer-Fantasie bei Biogen und den wichtigen Start in die amerikanische Berichtssaison. Darüber hinaus geht es um Biogen, Eisai, Fate Therapeutics, Atai Life Sciences, Gold, Bitcoin, Ether, BASF, Covestro, Lanxess, ThyssenKrupp, Continental, Brenntag, Fidelity Global Quality Income ETF (WKN: A2DL7E), Vanguard FTSE All-World High Dividend Yield ETF (WKN: A1T8FV). Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

On this episode of the SPEED CHANGE REPEAT Podcast we are talking with Florian Brand who is CEO and Co-Founder at ATAI Life Sciences.  The company is aiming to develop differentiated treatments for patients suffering from mental health orders. Having collected over $500m in capital with noteable backing from investors such as Cathie Wood at ARK Invest, ATAI is at the forefront when it comes to the psychedelics market.  Together with Florian we are covering the early founding of the company and dive deep into the company's funding model for compound development as well as the role of digital therapeutics in ATAI's treatment strategy. 

This episode is brought to you by Cozy Earth, InisdeTracker, and Rupa Health.If you or a loved one struggle with addiction, this is an episode you're going to want to listen to. Many of our current pharmaceuticals stem from compounds discovered in plant medicines. And many beneficial plants that were discovered decades ago still have huge potential for changing modern medicine—ibogaine is one of them. Today on The Doctor's Farmacy, I'm excited to sit down with Dr. Deborah Mash to discuss the use of the African plant ibogaine and its metabolite, noribogaine, in the treatment of addiction and how it could impact the devastating opioid epidemic. Dr. Deborah Mash is one of the world's foremost experts on ibogaine. She is the CEO and Founder of DemeRx Inc., a clinical-stage drug development company advancing ibogaine and its active metabolite noribogaine for the treatment of opioid use disorder. DemeRx has partnered with ATAI Life Sciences—a global biotech platform with a special focus on psychedelic medicine—to develop ibogaine for those suffering from opioid use disorder. Building on the extensive human data available around ibogaine, DemeRx and ATAI are conducting a Clinical Phase I/II trial in opioid-dependent patients. This landmark trial will advance screening procedures, dosing guidelines, and best practices for opioid withdrawal management and relapse prevention. This episode is brought to you by Cozy Earth, InisdeTracker, and Rupa Health.Cozy Earth makes the most comfortable, temperature-regulating, and nontoxic sheets on the market. Right now, get 40% off your Cozy Earth sheets. Just head over to cozyearth.com and use code MARK40.InsideTracker is a personalized health and wellness platform like no other. Right now they're offering my community 20% off at insidetracker.com/drhyman.Rupa Health is a place where Functional Medicine practitioners can access more than 2,000 specialty lab tests from over 20 labs like DUTCH, Vibrant America, Genova, and Great Plains. You can check out a free, live demo with a Q&A or create an account at RupaHealth.com.Here are more details from our interview (audio version / Apple Subscriber version):The long history of ibogaine's ethnobotanical and ethnopharmacological use (7:01 / 4:10) The power of ibogaine to reset opioid tolerance and bypass many withdrawal symptoms in a single dose (15:41 / 8:11) How ibogaine works (20:59 / 14:15) Using ibogaine to protect against future relapse (26:09 / 19:25) Efforts to understand the importance of ibogaine's psychedelic effects (30:05 / 24:54) Assessing the success rates of recovery and relapse prevention from ibogaine treatment (37:49 / 34:02) Understanding the underlying drivers of addiction for better recovery and relapse treatment (41:46 / 37:55) The concept of “psychoplastogens” and turning on synaptic plasticity in the brain (51:44 / 47:52) Humanity's relationship to plants and plant medicines (57:25 / 53:34) Risks associated with and considerations for seeking ibogaine treatment (1:03:24 / 59:37)Learn more about Dr. Mash's work at demerx.com. Hosted on Acast. See acast.com/privacy for more information.

Dr. Srinivas Rao, MD, Ph.D. is the Chief Scientific Officer at atai Life Sciences (https://www.atai.life/), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. With offices in New York, London and Berlin, atai's business model combines funding, technology, scientific and regulatory expertise with a focus on psychedelic therapeutic moieties, and other drugs, with differentiated safety profiles and therapeutic potential. Dr. Rao also serves as CEO of atai portfolio company, EntheogeniX (https://www.entheogenixbio.com/), a computational biophysics and artificial intelligence biotech working to design the next generation of psychedelics-inspired mental health drugs. Dr. Rao has over 19 years of professional experience in the pharmaceutical and biotechnology industries. Prior to atai, Dr. Rao has held the titles of Chief Scientific, Medical, or Executive Officer at companies ranging from venture-backed startups to vertically-integrated, publicly-traded pharmaceutical companies. Dr. Rao completed an internship in Internal Medicine at Yale-New Haven Hospital. He received his Ph.D. in neurobiology from Yale Graduate School and his M.D. from Yale School of Medicine. He holds both a Bachelor of Science and Master of Science degree in Electrical Engineering from Yale College and Yale Graduate School, respectively.

How atai Life Sciences CEO Florian Brand (ATAI) is leading the way in the emerging science of psychedelic drug development and revolutionizing psychiatric biotech medicine. Ford Motor Company (F) plans to change potentially every part of its business as it drives toward an EV future… We discuss how the automaker is securing the materials necessary to do so. Single-family homebuilder Century Communities (CCS) explains why higher rates may actually be a good thing for its inventory. Columbia Sportswear Company (COLM) wrestles with supply-chain problems. The Drill Down with Cory Johnson offers a regular look at the business stories behind stocks on the move. Learn more about your ad choices. Visit megaphone.fm/adchoices

It's our first real, live billionaire guest… Christian Angermayer, founder of ATAI Life Sciences, a startup that seeks to treat mental health disorders with psychedelics. But first, hear all about the four Polish grandpas who founded a quantum science startup because "retirement is boring”. We also called Miriam Partington, our Berlin correspondent, on a new movement coming out of Germany, called steward ownership, that promises startups an alternative to giving over equity and control of their company.

As the lead investor in Compass Pathways, Founder of Atai Life Sciences and Apeiron Investment Group, Christian is the perfect person to talk everything psychedelics in 2022. With a diverse portfolio across Fintech, Crypto, Life Sciences, Media, Entertainment and more, Christian is a true leader in spotting unique business opportunities and driving these organisations forward. Tune into Christian's interview today!Take a look at the full collection of podcasts and explore additional cannabis & psychedelics content on the GCI Content Hub: https://contenthub.gcintelligence.com/ 

Let's understand the business from the company that wants you to “live a more fulfilled life”.Industry: Biotechnology

On this week's episode, we welcome Bek Muslimov & Nikolay Tretiyakov, Co-Founders of Leafy Tunnel - early stage VC firm investing in psychedelics and cannabis to combat mental health and pain disorders.We examine the European investment landscape within the psychedelic and cannabis sector, looking into the types of investors and funds operational within this space, alongside how they have changed as the market begins to build momentum.→ View full show notes, summary, and access resources here: https://www.canverse.global/shownotes/e138About Nikolay TretiyakovNikolay is a Co-Founding Partner at Leafy Tunnel. Nikolay is an investor in ATAI Life Sciences (a biotech platform curing mental health disorders) and Iuvo Therapeutics (a European cannabis company).Prior to Leafy Tunnel, in 2013 Nikolay founded Blue Wire Capital, a multi-strategy investment firm investing in European venture funds, technology and life science companies.Nikolay holds a BA degree from the University of Wolverhampton and an MBA from the Russian Academy of National Economy.About Bek MuslimovBek is a Co-Founding Partner at Leafy Tunnel. For the past 7 years, he has been investing in European technology and life science companies. His recent investments include ATAI Life Sciences and Iuvo Therapeutics.Prior to Leafy Tunnel, Bek was the Investment Director at Blue Wire where he led investments in Monzo, Superawesome, Homehero, Ocean Harvest, and IhateironingBek is an MBA graduate of London Business School, has completed a medical neuroscience course at Duke University and holds a medical cannabis specialisation from the University of Colorado Boulder.ResourcesLeafy Tunnel's Website: https://www.leafytunnel.com/Join Bek on LinkedIn: https://www.linkedin.com/in/bekmuslimov/Join Nikolay on LinkedIn: https://www.linkedin.com/in/nikolaytretyakov/Follow Leafy Tunnel on LinkedIn: https://www.linkedin.com/company/leafy-tunnel/

In today's podcast, I spoke with Stephen Bright. Stephen is a clinically trained psychologist with a wealth of experience in both the fields of Addictions research and psychedelic research/advocacy. Stephen has been consistently pushing for a more nuanced and comprehensive discussion pertaining to sensible drug use in Australia, In today's podcast We Discuss; The TGA's interim decision to not amend the current scheduling of MDMA, The recent appointment of an independent expert panel to undertake a review into the potential therapeutic value of MDMA and psilocybin, The comparison of FDA and TGA scheduling, TGA's Special Access Scheme PRISM's position on the recent move to reschedule MDMA and Psilocybin, Stephen's desire to have these substances available through Australia's public health system, How Private and Public Sector healthcare service providers might best interface in the psychedelic space, The concept of ‘corporadelics', and Stephen's concern about large corporations like Atai Life Sciences and Compass Pathways potentially monopolizing the space, Tulip mania and the potential for a the emergence of a psychedelic stock bubble, The difference between decriminalization and the rescheduling of drugs National Drug Strategy Household Survey Data showing an uptick in the use of psychedelics The need to balance private venture with regulatory oversight and the U bend of regulation Stephen's experience at the rainbow serpent festival and dancewize Stephen's experience in training as an MDMA-assisted psychotherapist with MAPS, and watching Michael Mithoefer at work The potential for a general underestimation of the profundity of experience of the MDMA assisted psychotherapy, especially if the client has unprocessed trauma, The differences in integration patterns between psychedelic substances, Internal Family Systems and its relationship to MDMA assisted psychotherapy The difference between evidence-based and evidence informed practice The concept of inner healing intelligence and different models that may support MDMA, MDMA's capacity to produce visceral feelings of safety The work of Tobias Penno The documentary, ‘Trip of Compassion' Stephen's definition of the concept of ‘holding space' The need for Clinician's to have a personal experience of MDMA in order to more deeply understand the process The emergence of psychedelic integration circles in Australia Dr Bright's University course in addiction studies at Edith Cowan University The need for project managers and those with an understanding of drug development pathways to enter the space Stephen's Ted Talk How to Support the Australian Psychedelic Society, Entheogeneis Australis, and PRISM

DemeRx IB, Inc. CEO Deborah Mash joined Proactive New York to discuss the group's joint venture with Atai Life Sciences (NASDAQ:ATAI), focused on developing ibogaine to treat opioid use disorder. Mash says the group has recently dosed its first patient with an oral form of ibogaine DMX-1002 in a Phase 1/2a clinical trial at the Manchester clinical unit of MAC Clinical Research in the UK, in order to precisely define the therapeutic safety margin. Phase 1 data is expected by early 2022.

In der heutigen Folge „Alles auf Aktien“ berichten die Finanzjournalisten Anja Ettel und Holger Zschäpitz über den Dax ohne Mojo, Wahnsinn in Dänemark und wie man in der Mangelwirtschaft gut zurecht kommt. Außerdem geht es um Hornbach, Northern Data, Atai Life Sciences, Bed, Bath and Beyond, Virgin Galactic, Daimler, Daimler Trucks, Mercedes Benz, Covestro, Lanxess, Etsy, Amazon, Ziprecruiter und Amadeus Fire. "Alles auf Aktien" ist der tägliche Börsen-Shot aus der WELT-Wirtschaftsredaktion. Die Wirtschafts- und Finanzjournalisten Holger Zschäpitz, Anja Ettel, Philipp Vetter, Daniel Eckert und Nando Sommerfeld diskutieren im Wechsel über die wichtigsten News an den Märkten und das Finanzthema des Tages. Außerdem gibt es jeden Tag eine Inspiration, die das Leben leichter machen soll. In nur zehn Minuten geht es um alles, was man aktuell über Aktien, ETFs, Fonds und erfolgreiche Geldanlage wissen sollte. Für erfahrene Anleger und Neueinsteiger. Montag bis Freitag, ab 6 Uhr morgens. Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören.

Amanda Eilian, Founding Partner of _able Partners joins us to talk all things mental health startup investing. _able Partners is an early-stage VC firm supporting visionary founders in the positive living space. Their investments focus on companies that improve the daily lives of people, making them healthier, happier, and making their lives more meaningful. Some specific investment areas include mental health, addiction, women's health, sexual wellness, wellness broadly, coaching and continued learning, child care, and self-expression. Amanda has led incredible early stage investments in companies like Spring Health, Compass Pathways, ATAI Life Sciences, Alma, Alto Neuroscience, and many others. You can connect with Amanda here:  _able Partners Website, LinkedIn What If Fellowship: https://whatif.vc/fellowship   HERE ARE SOME OF THE THINGS WE TALKED ABOUT: Amanda shares her background that led her to venture investing, creating _able Partners, and the focus of _able Partners. We discuss the areas and companies where _able has focused on which have been stigmatized in the past including mental health and addiction. Amanda shares about her team, how they are non-traditional, and what that looks like in terms of their professional interactions as a company. We discuss current themes in the mental health space and where investors should be looking to get involved in this space including accessibility, personalized care, and measurement and monitoring. Amanda shares what type of funding _able is interested in, their focus in early stage investing, and what criteria they look for when choosing who to work with. We talk about why stigma is starting to decrease and the possible causes for this wave of de-stigmatization. We discuss the lack of access, the shortage of psychiatrists across the country, and more issues surrounding mental health care and Amanda shares her ideas for what needs to happen to address these issues.   Connect with the Stigma Podcast in the following ways: What If Fellowship, Website, Twitter, Facebook, LinkedIn, Email Connect with host Stephen Hays here: Stephen Hays Personal Website, Twitter, LinkedIn, What If Ventures (Mental Health Venture Fund)

This week on the Drug Science podcast, Professor Deborah Mash tells us about Ibogaine. A hallucinogenic compound derived from the roots of a West African shrub, sometimes used as a treatment for heroin or cocaine addiction.Professor Mash found herself trying to reverse the damage that cocaine had caused on the streets of Miami, Florida. To explore new and novel therapies, she took a flight to Amsterdam to examine whether a West African shrub could be cure to cocaine and heroin dependency.  Since that fateful trip, she's been at the forefront of Ibogaine and Noribogaine research in the US. Now, she's bringing that research to the UK for a landmark Ibogaine study in Manchester, England. Could Ibogaine be one of the most clinically significant advances in addiction medicine of the 21st century? Deborah Mash is one of the world's foremost experts on the hallucinogenic drug ibogaine. She is the CEO and Founder of DemeRx Inc., a clinical-stage drug development company advancing ibogaine and its active metabolite noribogaine for the treatment of opioid use disorder. DemeRx has partnered with ATAI Life Sciences -- a global biotech platform with a special focus on psychedelic medicine -- to develop ibogaine for those suffering from opioid use disorder. Building on the extensive human data available around ibogaine, DemeRx and ATAI will submit Clinical Trial Applications for a Phase II study in opioid-dependent patients. This joint venture will also develop screening procedures, dosing guidelines, and best practices for opioid withdrawal management to ensure patient safety.Enrol to the MAC Ibogaine Clinical trial DemeRxMiami's drug war Brain Endowment BankNational Institute on Drug Abuse (NIDA)CocaethyleneDrug Free America Howard LotsofNoribogaineRick Doblin Cerebellar Toxicity Buprenorphine U.S. Food and Drug Administration (FDA)PsilocybinMAC ManchesterAlexander Shulgin  Allopregnanolone (Brexanolone)  ★ Support this podcast ★

Im Interview: Christian Angermayer, Serial Entrepreneur und Gründer von Atai Life Sciences, über Magic Mushrooms und sein groß angelegtes Investment in die Entwicklung von psychoaktiven Substanzen zur Behandlung von Depressionen und Traumata. USA: Die westliche Führungsmacht ist demoliert! Der stellv. Chefredakteur von ThePioneer Gordon Repinski berichtet aus Usbekistan vom Drehkreuz der Evakuierungsflüge aus Kabul. Die Börsen-Reporterinnen Anne Schwedt und Annette Weisbach über die Notenbank-Konferenz in Jackson Hole und über den deutschen Einkaufsmanagerindex. Die Grünen möchten Lastenfahrräder subventionieren. Armin Laschet entschuldigt sich für Fehler beim Afghanistan-Einsatz.

The Interview: Christian Angermayer, founder of Apeiron Investments, Atai Life Sciences, and COMPASS Pathways, made headlines for attributing his decision to invest in Bitcoin to a trip on mushrooms, but his journey as an investor and advocate for psychedelics goes much deeper than the clickbait. In this interview with Mike Green, Angermayer discusses how he went from a successful investor living the straight edge life to founding and eventually IPOing two startups, which are at the cutting edge of research into how mushrooms and other psychedelics could revolutionize the way we think about treating mental health issues. Together, they discuss the parallels between the modern human experience and other times of great change, how this is manifesting itself in societal and individual angst, and why this might make today the perfect time for broader acceptance of these treatments. They also touch on Green's own personal experience with mushrooms and Angermayer's optimistic approach to investing in technologies driving human progress. Recorded on May 8, 2021. Learn more about your ad choices. Visit megaphone.fm/adchoices

In Part Two Normie, Dave, Russell, and Sarvesh continue their conversation about Atai Life Sciences and how the introduction of for-profit psychedelic pharmaceutical corporations have shifted capital away from non-profits. This episode gets extra wacky and dark as they dive into Atai Founder & Chairman Christian Angermayer's role on Rwandan president Paul Kagame's Advisory Council. According to Human Rights Watch, journalist Michela Wrong, Archbishop Desmond Tutu, various governments, and many other media outlets, Kagame is a tyrant who has murdered, disappeared, and arrested numerous political opponents, journalists, critics, and citizens. Co-hosts: Brian Normand, David Nickles, Russell Hausfeld, Sarvesh Ramprakash. Editor: Matt Payne Additional links:  The real life “Black Panther” miracle by Christian Angermayer Hotel Rwanda activist's daughter placed under Pegasus surveillance Christian Angermayer's ATAI Life Sciences is positioned to take the psychedelic throne from MAPS Analyzing the Atai Life Sciences IPO | Business Trip podcast Support: If you like the show please support us on Patreon or make a tax-deductible donation.  **Thank you to our Patreon podcast and video supporters: Reliable Spores, Houston Puck, Dave Hodges, Jon Hanna, James Hubbard, Lindsay Munson, Evan Freimuth, Abigail Bianchi, Meghan Kennedy, Dave Ayers, Darrell Duane, Tehseen Noorani, Tariqul Islam, Clifford Hudson, Daniel McQueen, Maryann Kehoe, Ben Yono, Nathan Espinosa, Annick McIntosh, Starbuck, Aaron Williams, Jenine Innes, Julia A, Jesse Liberty, Christian Dawley, Leon Boroditsky, Samy Tammam, Amanda Alexander, Jason Gross, Paige Hausfeld, John Bannon, Clifford Hudson, Sandra Dreisbach.

The Interview: Christian Angermayer, founder of Apeiron Investments, Atai Life Sciences, and COMPASS Pathways, made headlines for attributing his decision to invest in Bitcoin to a trip on mushrooms, but his journey as an investor and advocate for psychedelics goes much deeper than the clickbait. In this interview with Mike Green, Angermayer discusses how he went from a successful investor living the straight edge life to founding and eventually IPOing two startups, which are at the cutting edge of research into how mushrooms and other psychedelics could revolutionize the way we think about treating mental health issues. Together, they discuss the parallels between the modern human experience and other times of great change, how this is manifesting itself in societal and individual angst, and why this might make today the perfect time for broader acceptance of these treatments. They also touch on Green's own personal experience with mushrooms and Angermayer's optimistic approach to investing in technologies driving human progress. Recorded on May 8, 2021. Learn more about your ad choices. Visit megaphone.fm/adchoices

Brian Normand, David Nickles, and Russell Hausfeld are joined by new team member, Sarvesh Ramprakash, to discuss Atai Life Sciences' recent IPO on Nasdaq. They also discuss and provide updates on Russell's previous 2020 report exploring how the introduction of for-profit psychedelic pharmaceutical corporations has shifted capital away from non-profits. Watch: https://youtu.be/zijXN5GCgsk Co-hosts: Brian Normand, David Nickles, Russell Hausfeld, Sarvesh Ramprakash. Editor: Matt Payne Episode links:  Christian Angermayer's ATAI Life Sciences is positioned to take the psychedelic throne from MAPS No Direction Home by Norman Spinrad Analyzing the Atai Life Sciences IPO | Business Trip podcast Support: If you like the show please support us on Patreon or make a tax-deductible donation.  **Thank you to our Patreon podcast and video supporters: Reliable Spores, Houston Puck, Dave Hodges, Jon Hanna, James Hubbard, Lindsay Munson, Evan Freimuth, Abigail Bianchi, Meghan Kennedy, Dave Ayers, Darrell Duane, Tehseen Noorani, Tariqul Islam, Clifford Hudson, Daniel McQueen, Maryann Kehoe, Ben Yono, Nathan Espinosa, Annick McIntosh, Starbuck, Aaron Williams, Jenine Innes, Julia A, Jesse Liberty, Christian Dawley, Leon Boroditsky, Samy Tammam, Amanda Alexander, Jason Gross, Paige Hausfeld, John Bannon, Clifford Hudson, Sandra Dreisbach.

Hello and welcome back to Equity, TechCrunch's venture capital-focused podcast, where we unpack the numbers behind the headlines.For this week's deep dive, Alex and Natasha and Danny decided that it was time to talk about drugs. No, not like drugs for fun, but instead drugs that you might have considered fun, but are now being redirected to help bolster your health.Yep, that's our theme today. As it turns out, there are a number of startups and even nascently public companies that are pursing using drugs that we might consider recreational for serious health purposes. Which is neat, as our habit of decrying any drug that makes you feel better as immoral has likely held us back from learning quite a lot about them.Venture capital investment in psychedelic start-ups, per CB Insights, rose from sub-$100 million results in 2018 and 2019 to $346 million last year.Vice clauses, however, can pause a legitimate issue for investors who might want to cut a check in the space.From the startup angle, NUE Life Health recently raised $3.3 million, and Osmind is up to some neat stuff regarding mental health.From the public markets, Atai Life Sciences, Compass Pathways, and MindMed are the companies worth watching.Frankly this was a fun one to record, even if the topic at hand is actually rather serious. Chat Friday morning!

In Part Two, the Psymposia crew continues to deconstruct a conversation between two self-described entrepreneurs who recently discussed psychedelics and medicalization during an event called Psychedelic Capitalism with Alexander Beiner [Rebel Wisdom] and Lars Wilde [COMPASS Pathways, Atai Life Sciences]— while studiously avoiding a debate of capitalism altogether. Watch: https://www.youtube.com/watch?v=WNHX3OIO3-4 Co-hosts: Neşe Devenot, Brian Pace, Brian Normand, David Nickles. Editor: Matt Payne If you like the show please support us on Patreon or make a tax-deductible donation.  **Thank you to our Patreon podcast and video supporters: Reliable Spores, Houston Puck, Dave Hodges, Jon Hanna, James Hubbard, Lindsay Munson, Evan Freimuth, Abigail Bianchi, Meghan Kennedy, Dave Ayers, Darrell Duane, Tehseen Noorani, Tariqul Islam, Clifford Hudson, Daniel McQueen, Maryann Kehoe, Ben Yono, Nathan Espinosa, Annick McIntosh, Starbuck, Aaron Williams, Jenine Innes, Julia A, Jesse Liberty, Christian Dawley, Leon Boroditsky, Samy Tammam, Amanda Alexander, Jason Gross, Paige Hausfeld, John Bannon, Clifford Hudson, Sandra Dreisbach.

Hello and welcome back to Equity, TechCrunch's venture capital-focused podcast, where we unpack the numbers behind the headlines.For this week's deep dive, Alex and Natasha and Danny decided that it was time to talk about drugs. No, not like drugs for fun, but instead drugs that you might have considered fun, but are now being redirected to help bolster your health.Yep, that's our theme today. As it turns out, there are a number of startups and even nascently public companies that are pursing using drugs that we might consider recreational for serious health purposes. Which is neat, as our habit of decrying any drug that makes you feel better as immoral has likely held us back from learning quite a lot about them.Venture capital investment in psychedelic start-ups, per CB Insights, rose from sub-$100 million results in 2018 and 2019 to $346 million last year.Vice clauses, however, can pause a legitimate issue for investors who might want to cut a check in the space.From the startup angle, NUE Life Health recently raised $3.3 million, and Osmind is up to some neat stuff regarding mental health.From the public markets, Atai Life Sciences, Compass Pathways, and MindMed are the companies worth watching.Frankly this was a fun one to record, even if the topic at hand is actually rather serious. Chat Friday morning!

Atai Life Sciences (NASDAQ:ATAI) is a mental health biotech company developing novel drugs (psychedelic and non-psychedelic) to cure various mental health diseases such as addiction, depression, anxiety, and PTSD. Atai recently raised $225 million in an upsized Nasdaq IPO. This impressive public offering values the company north of $2 billion. Why the excitement for another […]

Christian Angermayer ist Investor, Innovator und Vordenker zahlreicher bahnbrechender Technologien. Nur wenige andere deutsche Unternehmer faszinieren die Öffentlichkeit so wie Angermayer. Aus dem Nichts heraus baute er eines der interessantesten Portfolios der Welt auf. Biotechnologie, Psychopharmaka, Raumfahrt und Langlebigkeit sind seine Hauptthemen – sie faszinieren ihn seit jungen Jahren und haben ihm bedeutende Erfolge beschert. Zuletzt brachte er Atai Life Sciences an die New Yorker Börse, ein Berliner Unternehmen, das Wirkstoffe aus psychedelischen Pilzen in Medikamente verwandelt. Andere seiner Beteiligung arbeiten an dem Sieg über das Altern und dem Verzögern des Todes. Im Gespräch mit Christoph Keese berichtet Angermayer, wie er denkt, was ihn antreibt, wofür er arbeitet und wie ihm seine Spiritualität als Inspiration und Kraftquelle dient. Leidenschaftlich, engagiert, reflektiert und immer interessant berichtet Christian Angermayer aus seinem Leben und von seinen Interessen. Eine Folge, die hören sollte, wer dem Geheimnis erfolgreicher Unternehmer auf die Spur kommen möchte.

The Psymposia crew deconstructs a conversation between two self-described entrepreneurs who recently discussed psychedelics and medicalization during an event called Psychedelic Capitalism with Alexander Beiner [Rebel Wisdom] and Lars Wilde [COMPASS Pathways, Atai Life Sciences]— while studiously avoiding a debate of capitalism altogether. Watch: https://www.youtube.com/watch?v=WNHX3OIO3-4 Read: https://newrepublic.com/article/159019/break-big-pharma-monopoly-covid-19-vaccine Co-hosts: Neşe Devenot, Brian Pace, Brian Normand, David Nickles. Editor: Matt Payne If you like the show please support us on Patreon or make a tax-deductible donation.  **Thank you to our Patreon podcast and video supporters: Reliable Spores, Houston Puck, Dave Hodges, Jon Hanna, James Hubbard, Lindsay Munson, Evan Freimuth, Abigail Bianchi, Meghan Kennedy, Dave Ayers, Darrell Duane, Tehseen Noorani, Tariqul Islam, Clifford Hudson, Daniel McQueen, Maryann Kehoe, Ben Yono, Nathan Espinosa, Annick McIntosh, Starbuck, Aaron Williams, Jenine Innes, Julia A, Jesse Liberty, Christian Dawley, Leon Boroditsky, Samy Tammam, Amanda Alexander, Jason Gross, Paige Hausfeld, John Bannon, Clifford Hudson, Sandra Dreisbach

In der heutigen Folge „Alles auf Aktien“ berichten die Finanzjournalisten Nando Sommerfeldt und Holger Zschäpitz über Seltsames bei Air Berlin, die nächsten Newcomer, wie man vom 750-Milliarden-Euro-Rettungsfonds profitiert und Unternehmen, die die Psyche der Welt heilen wollen. Außerdem geht es um Adidas, Puma, Nike, Hornbach Holding, Cherry, Mr Spex, Bike24, Eli Lilly, Atai Life Sciences, Mind Medicin, Compass Pathways, Siemens Gamesa, Vestas, RWE, Orsted, Iberdrola, Enel, VW, Deutsche Telekom, ASML, Infineon, SAP, iShares STOXX Europe 600 Technology (WKN: A0H08Q). Am 5. Juli startet die "Alles auf Aktien Academy". In dem 5-teiligen Sommer-Special gibt es jede Woche freitags einen Experten-Talk zu Investmentideen. Den täglichen Börsen-Shot hört Ihr wieder ab dem 9. August. "Alles auf Aktien" ist der tägliche Börsen-Shot aus der WELT-Wirtschaftsredaktion. Die Wirtschafts- und Finanzjournalisten Anja Ettel und Holger Zschäpitz diskutieren über die wichtigsten News an den Märkten und das Finanzthema des Tages. Außerdem gibt es jeden Tag eine Inspiration, die das Leben leichter machen soll. In nur zehn Minuten geht es um alles, was man aktuell über Aktien, ETFs, Fonds und erfolgreiche Geldanlage wissen sollte. Für erfahrene Anleger und Neueinsteiger. Montag bis Freitag, ab 6 Uhr morgens. Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++Werbung+++ Hier geht's zur App: Scalable Capital ist der Broker mit Flatrate. Unbegrenzt Aktien traden und alle ETFs kostenlos besparen – für nur 2,99 € im Monat, ohne weitere Kosten. Und jetzt ab aufs Parkett, die Scalable App downloaden und loslegen. Hier geht's zur App: https://bit.ly/3abrHQm

Episode 107! The Biz Bites N' More Podcast covers the recent psychedelic trend with more companies IPO'ing from Woodstock's medicine. COVID is over but vaccines and pills are not, the US government just put 3 billion towards stopping the next pandemic. Finally, Gyms are back and every American has just been waiting to sweat in front of others.... weird but ok. $PTON $ATAI $PFE #Comedy #Business Blog: bizbitesnmore.com Twitter: @bizbitesnmore Facebook: @bizbitesnmore YouTube: Biz Bites N' More Leave a voice message on anchor or leave a five star review on Apple and we will read it aloud/listen to it on the pod! VM: https://anchor.fm/biz-bites-n-more/message --- Send in a voice message: https://anchor.fm/biz-bites-n-more/message Support this podcast: https://anchor.fm/biz-bites-n-more/support

Today's episode features three experts, Josh Hardman, Michael Haichin, and Graham Pechenik as they analyze atai's S-1 in advance of their IPO. In this episode, we discuss:How atai went from idea to IPO in 3 yearsAn overview of atai's drug development programs and enabling technologiesThe platform's strategy and risksLinks to topics in this episode:Atai life sciencesEtifoxineEsketamine & arketamineAtai's S-1Psychedelic Pharmacist AssociationCalyx LawPsilocybin Alpha, Noetic Fundkratom, Salvinorin A, BNC210, mitragynineMike Novogratz, Christian Angermayer, George Goldsmith, Ekaterina Malievskaia, Peter ThielPureTech Health, Akili Interactive LabsBT's DemeRx EpisodeViridia Life Sciences, EmpathBio, Kures, Recognify Life SciencesRead the transcript here.Watch episode 9 on YouTube.Created by Greg Kubin and Matias SerebrinskyHost: Matias SerebrinskyProduced by Jonathan Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional music: The Innovation by Zack Frank (our very own sound engineer

Heute besprechen wir zusammen mit unserem Biotech-Autoren Paul das Unternehmen ATAI Life Sciences. Atai Life Sciences ist ein 2018 gegründetes in Berlin ansässiges Biotechnologieunternehmen, welches sich auf die Entwicklung von Medikamenten zur Therapie psychischer Störungen mit einem Fokus auf Psychedelika spezialisiert hat.

Atai Life Sciences is the most highly anticipated psychedelic IPO of 2021. It has a pipeline of 10 drugs, owns a large piece of Compass Pathways, and is also researching digital therapeutics and brain computer interfaces. When it IPOs it will likely be the psychedelic company with the largest market cap. In this episode of Brom Talks, we peek behind the curtain of Atai, and try to see if this valuation is justified. In doing so, we answer questions like: Who is Christian Angermayer? What does Atai's pipeline look like? What are the implications of Atai's unorthodox corporate structure? It is even fair to call Atai a psychedelics company? And we also compare and contrast this company with MindMed.

Der umtriebige Investor Christian Angermayer hat gerade das Closing seines Fonds Presight Capital bekannt gegeben. Insgesamt 290 Millionen Euro (350 Millionen Dollar) konnte er von zahlreichen Prominenten und Wirtschaftsgrößen einwerben, u.a. der Schauspielerin Uma Thurman, dem frühere Goldman-Sachs-CFO Martin Chavez und den Investmentgesellschaften von Xing-Gründer Lars Hinrich und Finanzunternehmerin Nicole Junkermann. Angermayer selbst investiert 60 Millionen Dollar. Ebenfalls in der vergangenen Woche hatte Angermayer die Finanzierungrunde für seinen Psychedelika-Inkubator Atai Life Sciences bekannt gegeben. Hier konnte er 130 Millionen Euro einwerben. Und ebenfalls letzte Woche er war Lead-Investor bei der 30 Millionen Dollar-Runde in die Kölner Trading-App Nextmarkets. Stoff genug für ein spannendes kurzweiliges Interview.

This week we reflect on holiday spirit, random acts of kindness, paying it forward, Mike Tyson's return to the boxing ring - fueled by 5-MeO-DMT Toad Venom: “I took the medicine and the medicine told me to get into shape" says Tyson [https://www.news.com.au/sport/boxing/the-psychedelic-drug-concoction-that-fuelled-mike-tysons-return/news-story/0df9004a842cc8b80fd1281e560e57d6], billionaire Peter Thiel invests $12M in ATAI Life Sciences (& Compass Pathways) a start-up developing synthetic psychedelic drugs [https://www.cnbc.com/2020/11/23/peter-thiel-backs-psychedelics-startup-atai.html], combining psilocybin and cannabis has never caused a health emergency [https://www.leafly.com/news/health/combining-cannabis-with-psychedelic-mushrooms-recipe-for-mind-expansion-or-a-bad-trip], ketamine treatment 'Roots to Thrive' being used to treat PTSD in health-care workers [https://vancouverisland.ctvnews.ca/new-psychedelic-treatment-being-used-to-treat-ptsd-in-health-care-workers-1.5206639], Jeff Bezos spends billions on his 'Earth Fund' while Amazon is monitoring Greta Thunberg's Twitter & climate change groups as potential threats [https://www.businessinsider.com/amazon-jeff-bezos-climate-change-groups-greta-thunberg-2020-11], Chinese President Xi urged soldiers to step up combat training and 'not to fear death and hardship' [https://www.dailymail.co.uk/news/article-8993473/Chinese-President-Xi-tells-army-not-fear-death-prepare-win-wars.html], Adamson BBQ, in Toronto, fights lockdowns asking why can box stores can be open while small business are shut? at its pinnacle had dozens of police officers surrounding the property [https://torontosun.com/news/local-news/warmington-out-of-jail-on-bail-skellys-bbq-revolt-rolls-on] & more... Thanks for listening to RAP DRUGS POD: the Research And Psychedelic Drugs Show, from Jason & Todd - you can watch the pod here: https://www.periscope.tv/w/1vOxwEwejbMGB?autoplay New episodes for #theRAPDrugsPod go live every Sunday IG TV > https://instagram.com/rapdrugspod Twitter > https://twitter.com/rapdrugspod Periscope > https://pscp.tv/rapdrugspod/follow YouTube (clips) > https://youtube.com/channel/UC7-KjFai4_I1Uhd3xaRQExg Merch > https://teespring.com/stores/rapdrugs Pay-What-You-Can > https://paypal.me/rapdrugspod Contact: therapdrugspod@gmail.com (202) 594-9466 © 2020 - Bong Toke Productions. All Rights Reserved.

Ever wondered how psychedelics can change your life? Or are you just curious to learn more about how psychedelics can be a gateway into expanded consciousness, healing, and more? In this week's episode, I interview my friend and guest, Dina Burkitbayeva who is a serial entrepreneur and investor in the mental health space. Her fund's (Forward Vision Fund) investments include ATAI Life Sciences, COMPASS Pathways, The Third Wave among others. Dina is very passionate about supporting companies and institutions building alternative solutions to mental health and helping promote the message that there are more ways to treat mental health than just medication and talk therapy. Dina runs an investment syndicate on Angelist focused on pre-seed and seed companies in the alternative mental health and higher consciousness companies. She also runs a newsletter focused on latest news and trends in the investment and business aspects of the psychedelics therapeutic space. In this conversation, we cover the following: 1. What are psychedelics? 2. The most widely used psychedelics like Psilocybin, Ayahuasca, ibogaine and Ketamine 3. Why have they become so popular and which companies to look out for in this space 4. How can they be used to heal mental health and specifically anxiety and depression 5. How you can invest in this space 6. Stories of healing from people who have used them when nothing else worked Follow @Gateways_To_Awakening On Instagram if you'd like to stay connected. I'd love to hear from you and learn more about what topics you'd like to learn about, and which shows and topics you enjoyed the most!